Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mouse models of prostate cancer

Oncogene volume 18, pages 5349–5355 (1999)Cite this article

Abstract

The pathogenetic basis of prostate cancer remains highly elusive; its clarification could be facilitated greatly by laboratory and clinical models of the disease. Although the genetically manipulated mouse has been invaluable for the modeling of other human cancer types, it has fared less well with respect to prostate cancer. Nevertheless, several highly valuable transgenic models exist and are highlighted in this review. Emerging reagents and strategies may allow us to use the mouse more effectively to define the molecular, cellular and physiological events that lead to prostate cancer initiation and progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Abbreviations

BPH:

benign prostatic hyperplasia

CGH:

comparative genomic hybridization

FISH:

fluorescence in situ hybridization

MAR:

matrix association region

MMTV-LTR:

mouse mammary tumor virus long terminal repeat

MPR:

mouse prostate reconstitution

PIN:

prostatic intraepithelial neoplasia

PSA:

prostate specific antigen

PSBP:

prostatic steroid binding protein

SCID:

severe combined immunodeficient

TRAMP:

transgenic adenocarcinoma mouse prostate

References

  • Barrios R, Lebovitz RM, Wiseman AL, Weisoly DL, Matusik RJ, DeMayo F and Lieberman MW. . 1996 Transgenics 2: 23–28.

  • Barrios R, Rangdaeng S, Huang S, Chevez-Barrios P, Lebovitz R and Lieberman MW. . 1994 Transgenics 1: 411–415.

  • Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C and Shen MM. . 1999 Genes Dev. 13: 966–977.

  • Brothman AR, Maxwell TM, Cui J, Deubler DA and Zhu XL. . 1999 Prostate 38: 303–312.

  • Buttyan R. . 1997 Prostate 33: 164–165.

  • Carter BS, Epstein JI and Isaacs WB. . 1990 Cancer Res. 50: 6830–6832.

  • Choi YW, Henrard D, Lee I and Ross SR. . 1987 J. Virol. 61: 3013–3019.

  • Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW and Trapman J. . 1997 Mol. Endocrinol. 11: 1256–1265.

  • Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J and Scher HI. . 1998 J. Natl. Cancer Inst. 90: 1284–1291.

  • Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ and Sugimura Y. . 1987 Endocrinol. Rev. 8: 338–362.

  • De Marzo AM, Coffey DS and Nelson WG. . 1999 Urology 53: 29–39; discussion 39–42.

  • Di Cristofano A, Pesce B, Cordon-Cardo C and Pandolfi PP. . 1998 Nat. Genet. 19: 348–355.

  • di Sant'Agnese PA. . 1998 Prostate Suppl. 8: 74–79.

  • Donjacour AA, Thomson AA and Cunha GR. . 1998 Differentiation 62: 227–237.

  • Egawa S, Kadmon D, Miller GJ, Scardino PT and Thompson TC. . 1992 Mol. Carcinog. 5: 52–61.

  • Foster BA, Gingrich JR, Kwon ED, Madias C and Greenberg NM. . 1997 Cancer Res. 57: 3325–3330.

  • Furth PA. . 1998 Dev. Biol. Stand. 94: 281–287.

  • Garabedian EM, Humphrey PA and Gordon JI. . 1998 Proc. Natl. Acad. Sci. USA 95: 15382–15387.

  • Ghoniem GM. and VandenBerg TL. . 1994 Neurourol. Urodyn. 13: 91–96.

  • Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ and Greenberg NM. . 1997 Cancer Res. 57: 4687–4891.

  • Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM and Greenberg NM. . 1996 Cancer Res. 56: 4096–4102.

  • Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ and Scher HI. . 1998 Prostate 36: 59–63.

  • Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM. . 1995 Proc. Natl. Acad. Sci. USA 92: 3439–3443.

  • Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. 1994 Mol. Endocrinol. 8: 230–239.

  • Haggman MJ, Macoska JA, Wojno KJ and Oesterling JE. . 1997 J. Urol. 158: 12–22.

  • Hall SJ, Mutchnik SE, Chen SH, Woo SL and Thompson TC. . 1997 Int. J. Cancer 70: 183–187.

  • Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M and Thompson TC. . 1999 Cancer Gene Ther. 6: 54–63.

  • Hennighausen L, McKnight R, Burdon T, Baik M, Wall RJ and Smith GH. . 1994 Cell Growth Differ. 5: 607–613.

  • Isaacs W. . 1998 The Genetic Basis of Human Cancer. Vogelstein B and Kinzler KW. (eds) McGraw-Hill, Health Professions Division: New York pp. 653–660.

    Google Scholar 

  • Kaplan PJ, Mohan S, Cohen P, Foster BA and Greenberg NM. . 1999 Cancer Res. 59: 2203–2209.

  • Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML and Matusik RJ. . 1998 Lab Invest 78: i–xv.

  • Kinzler KW and Vogelstein B. . 1996 Cell 87: 159–170.

  • Kitsberg DI and Leder P. . 1996 Oncogene 13: 2507–2515.

  • Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA and Smithies O. . 1998 Proc. Natl. Acad. Sci. USA 95: 15677–15682.

  • Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB and Allison JP. . 1997 Proc. Natl. Acad. Sci. USA 94: 8099–8103.

  • Landis SH, Murray T, Bolden S and Wingo PA. . 1998 CA Cancer J. Clin. 48: 6–29.

  • Lee WH, Isaacs WB, Bova GS and Nelson WG. . 1997 Cancer Epidemiol Biomarkers Prev. 6: 443–450.

  • Levine AJ. . 1990 Bioessays 12: 60–66.

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R. . 1997 Science 275: 1943–1947.

  • Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T and Watkins BA. . 1998 Prostate 36: 49–55.

  • Maini A, Archer C, Wang CY and Haas GP. . 1997 In Vivo 11: 293–299.

  • Maroulakou IG, Anver M, Garrett L and Green JE. . 1994 Proc. Natl. Acad. Sci. USA 91: 11236–11240.

  • Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT and Thompson TC. . 1991 Mol. Endocrinol. 5: 503–513.

  • Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P and Leder P. . 1990 EMBO J. 9: 907–913.

  • Perez-Stable C, Altman NH, Brown J, Harbison M, Cray C and Roos BA. . 1996 Lab. Invest. 74: 363–373.

  • Perez-Stable C, Altman NH, Mehta PP, Deftos LJ and Roos BA. . 1997 Cancer Res. 57: 900–906.

  • Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE and Parsons R. . 1999 Proc. Natl. Acad. Sci. USA 96: 1563–1568.

  • Price D. . (1963) In: Vollmer EP and Kauffman G. (eds). Biology of the Prostate and Related Tissues. US Government Printing Office: Washington, DC pp. 1–28.

    Google Scholar 

  • Pylkkanen L, Makela S and Santti R. . 1996 Eur. Urol. 30: 243–248.

  • Qian J, Jenkins RB and Bostwick DG. . 1999 Eur. Urol. 35: 479–483.

  • Ren C, Yang G, Timme TL, Wheeler TM and Thompson TC. . 1998 Cancer Res. 58: 1285–1290.

  • Royai R, Lange PH and Vessella R. . 1996 Semin. Oncol. 23: 35–40.

  • Schaffner DL, Barrios R, Shaker MR, Rajagopalan S, Huang SL, Tindall DJ, Young CY, Overbeek PA, Lebovitz RM and Lieberman MW. . 1995 Lab. Invest. 72: 283–290.

  • Schreiber-Agus N, Meng Y, Hoang T, Hou Jr H, Chen K, Greenberg R, Cordon-Cardo C, Lee HW and DePinho RA. . 1998 Nature 393: 483–487.

  • Sciavolino PJ and Abate-Shen C. . 1998 Ann. Med. 30: 357–368.

  • Shi XB, Gumerlock PH and deVere White RW. . 1996 World J. Urol. 14: 318–328.

  • Shibata MA, Jorcyk CL, Liu ML, Yoshidome K, Gold LG and Green JE. . 1998 Toxicol. Pathol. 26: 177–182.

  • Shibata MA, Ward JM, Devor DE, Liu ML and Green JE. . 1996 Cancer Res. 56: 4894–4903.

  • Skalnik DG, Dorfman DM, Williams DA and Orkin SH. . 1991 Mol. Cell. Biol. 11: 4518–4527.

  • Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB and Thompson TC. . 1993 Cancer Res. 53: 4461–4465.

  • Small EJ. . 1998 Curr. Opin. Oncol. 10: 244–252.

  • Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow II TG and Thalmann GN. . 1998 Prostate 36: 56–58.

  • Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M and Mak TW. . 1998 Curr. Biol. 8: 1169–1178.

  • Tehranian A, Morris DW, Min BH, Bird DJ, Cardiff RD and Barry PA. . 1996 Am. J. Pathol. 149: 1177–1191.

  • Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT and Park SH. . 1991 Cancer Surv. 11: 55–71.

  • Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D and Yang G. . 1995 Oncogene 10: 869–879.

  • Thompson TC, Southgate J, Kitchener G and Land H. . 1989 Cell 56: 917–930.

  • Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S and Yoshida K. . 1993 Mol. Carcinog. 7: 165–179.

  • Tutrone Jr RF, Ball RA, Ornitz DM, Leder P and Richie JP. . 1993 J. Urol. 149: 633–639.

  • Waters DJ, Bostwick DG and Murphy GP. . 1998a Prostate 36: 47–48.

  • Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC and Tindall DJ. . 1998b Prostate 36: 64–67.

  • Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK and Frelinger JG. . 1998 Int. J. Mol. Med. 2: 487–496.

  • Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK and Frelinger JG. . 1997 Proc. Natl. Acad. Sci. USA 94: 6369–6374.

  • Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM and Frelinger JG. . 1998 Int. J. Mol. Med. 1: 379–386.

  • Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML and Matusik RJ. . 1997 Prostate 32: 129–139.

  • Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT and Thompson TC. . 1998 Clin. Cancer Res. 4: 1873–1880.

  • Zhang X, Chen MW, Ng A, Ng PY, Lee C, Rubin M, Olsson CA and Buttyan R. . 1997 Prostate 32: 16–26.

  • Zlotta AR and Schulman CC. . 1999 Eur. Urol. 35: 498–503.

Download references

Acknowledgements

The authors thank Dr Raju Kucherlapati for critical reading of this review. We apologize for any citations that may have been omitted. N Schreiber-Agus is supported by a Special Fellowship from the Leukemia Society of America and by funding from the Department of Defense Prostate Cancer Research Program.

Author information

Authors and Affiliations

  1. Department of Molecular Genetics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, New York, USA

    Prerna Sharma & Nicole Schreiber-Agus

Authors
  1. Prerna Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole Schreiber-Agus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, P., Schreiber-Agus, N. Mouse models of prostate cancer. Oncogene 18, 5349–5355 (1999). https://doi.org/10.1038/sj.onc.1203037

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203037

Keywords

This article is cited by

Search

Advanced search

Quick links